GleamWall
中文EN

ARDX ARDELYX, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1437402 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.6%
TTM net income YoY1.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—

Margins

Gross margin94.5%
Operating margin-7.7%
Net margin-11.8%
FCF margin-3.4%
EBITDA margin-7.1%

Returns

ROE-34.9%
ROA-10.3%
ROIC (approx.)-8.3%
Asset turnover0.87x

Leverage & solvency

Liabilities / assets72.1%
Debt / equity1.54x
Current ratio3.45x
Interest coverage-1.63x

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$127.66M$120.88M$94.47M$125.22M$110.33M$97.66M$74.11M$116.13M
Cost of revenue$4.54M$5.76M$4.81M$10.85M$3.98M$12.40M$12.30M$18.26M
Gross profit$123.12M$115.12M$89.66M$114.37M$106.35M$85.26M$61.81M$97.86M
R&D expense$25.20M$26.10M$20.19M$22.86M$18.07M$15.67M$14.94M$13.67M
SG&A expense$93.89M$101.44M$102.27M$86.41M$83.61M$83.99M$83.22M$76.07M
Operating income$4.02M-$12.43M-$32.79M$5.10M$4.67M-$14.39M-$36.35M$8.12M
Interest expense$5.88M$4.96M$5.60M$5.76M$5.80M$4.36M$4.19M$3.97M
Pretax income-$647,000-$16.61M-$37.60M-$400,000-$867,000-$19.08M-$40.28M$4.68M
Income tax$90,000$110,000$8,000$7,000$102,000$1,000$859,000$35,000
Net income-$737,000-$16.72M-$37.60M-$407,000-$969,000-$19.08M-$41.14M$4.64M
EBITDA$4.64M-$11.82M-$31.88M$6.02M$5.57M-$13.76M-$35.75M$8.64M
EPS (basic)0.00-0.07-0.15—0.00-0.08-0.17—
EPS (diluted)0.00-0.07-0.15—0.00-0.08-0.17—
Weighted avg. shares (diluted)250.01M248.07M245.86M—241.91M239.93M238.62M—
Balance sheet
Cash & equivalents$46.32M$97.19M$31.21M$68.00M$42.72M$90.05M$30.81M$64.93M
Short-term investments$239.02M$184.64M$206.87M$196.69M$199.99M$148.41M$183.14M$185.17M
Receivables$93.44M$100.35M$82.84M$71.85M$76.61M$62.55M$46.47M$57.70M
Inventory$157.56M$138.99M$128.03M$123.11M$129.36M$123.26M$105.88M$91.18M
Current assets$441.39M$441.93M$381.87M$382.32M$367.99M$351.57M$312.69M$356.45M
PP&E, net$1.57M$1.78M$2.00M$2.18M$2.07M$2.14M$1.67M$1.50M
Total assets$587.52M$575.89M$504.51M$501.60M$486.17M$466.77M$410.19M$435.75M
Current liabilities$127.81M$132.22M$109.57M$88.61M$83.39M$81.72M$75.84M$77.83M
Long-term debt$252.36M$251.82M$203.52M$202.83M$202.14M$201.45M$151.30M$150.85M
Total debt$252.36M$251.82M$203.52M$202.83M$202.14M$201.45M$151.30M$150.85M
Total liabilities$423.48M$426.88M$355.88M$334.65M$331.89M$327.24M$264.52M$262.46M
Shareholders' equity$164.05M$149.01M$148.62M$166.95M$154.28M$139.53M$145.68M$173.29M
Net debt$206.04M$154.63M$172.31M$134.84M$159.42M$111.40M$120.49M$85.92M
Shares outstanding251.03M249.15M246.97M244.35M242.97M240.77M239.20M238.02M
Cash flow statement
Operating cash flow$2.17M-$6.40M-$32.24M$20.95M$365,000-$25.34M-$38.46M$9.81M
Capital expenditure$0$13,000$69,000$361,000$156,000$650,000$325,000$593,000
Free cash flow$2.17M-$6.41M-$32.31M$20.59M$209,000-$25.99M-$38.78M$9.22M
Investing cash flow-$54.00M$22.66M-$9.99M$3.78M-$50.51M$34.92M$2.85M-$41.62M
Financing cash flow$959,000$49.72M$5.44M$557,000$2.81M$49.66M$1.48M$49.31M
Depreciation & amortization$621,000$604,000$915,000$921,000$905,000$631,000$602,000$515,000
Stock-based compensation$15.10M$15.32M$14.16M$12.45M$12.74M$11.69M$12.09M$9.86M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.